Device Development
Device Development
Dr. Harold Dauerman has utilized both single center and multi-center registry studies to elucidate the interventional cardiology treatment options for high risk patient subsets—those with in stent restenosis, bifurcation lesions, ST elevation AMI and cardiogenic shock. Currently, our research focus has been on the identification of high risk patients undergoing PCI characterized with analysis of systemic markers of inflammation, and the impact of anti-inflammatory treatment options on outcomes in risk patients. Photo: An early cardiac PET machine developed by our group.
An additional focus has been improving outcomes during and after PCI by taking advantage of information gained by evaluating biochemical effects of administration of antiplatelet agents. We have recently delineated platelet reactivity as a predictor of outcome during and following PCI. Further work is currently underway to characterize responses of patients to long-term administration of antiplatelet agents.
Recent Grant Support
Multicenter Clinical Trials (Site Principal Investigator):
DELIVER: Randomized comparison of drug-eluting (paclitaxel) versus stainless steel stenting. 2002-2003
STEAMI Trial: Efficacy of Intraveneous MC-135 as and adjunct to Primary PCI: 2003.
Investigator Initiated Studies (Industry Grants):
ESIS:Enhanced Suppression of Inflammation after Stenting: 2002-03
ESIS High Risk: Inflammation after stenting in high risk subgroups: 2003
Representative Publications
Dauerman HL, Baim DS, Cutlip DC, Sparano AM, Gibson CM, Carrozza JP, Garber GS, Kuntz RE, Cohen DJ. Mechanical debulking versus balloon angioplasty for the treatment of diffuse in-stent restenosis. American Journal of Cardiology, 1998; 82:277-84.
Dauerman HL, Higgins PH, Sparano AM, Gibson CM, Carrozza JP, Kuntz RE, Baim DS, Cohen DJ. Debulking versus balloon angioplasty for the treatment of true bifurcation lesions. Journal of the American College of Cardiology 1998; 32: 1845-52.
Cohen DJ, Dauerman HL. Treatment of diffuse coronary lesions: a time for randomized trials. American Heart Journal 1999; 137: 193-195.
Dauerman HL, Pinto DS, Ho KKL, Lorell BH, Cohen DJ, Kuntz RE, Baim DS, Carrozza JP. Acute infarct angioplasty in an unselected population: differential results in trial eligible and ineligible patients. Catheterization and Cardiovascular Intervention, 2000; 49: 237-243.
Dauerman HL, Prpic R, Andreou CS, Popma JJ. Resolution of coronary thrombus with rescue stenting. The American Journal of Cardiology, 2000; 85: p 1244-1247.
Dauerman HL, Yarzebski J, Lessard D, Furman MI, Gore JH, Goldberg RJ. Ten year trends in the incidence, outcome and treatment of Q wavemyocardial infarction. The American Journal of Cardiology 2000; 86:730-735.
Dauerman HL, Goldberg RJ, Malinski M, Yarzebski J, Lessard D, Gore JM. Outcomes and early revascularization for elderly patients with acute myocardial infarction complicated by cardiogenic shock: a population based perspective. Am J Cardiol, 2001;87:844-848.
Furman MI, Dauerman HL, Goldberg RJ, Yarzebski J, Lessard D, Gore JM. Twenty two year trends in the incidence, in hospital and long term case fatality rates from initial Q wave and non-Q wave MI: a community wide perspective. J Am Coll Cardiol, 2001;37:1571-80.
Dauerman HL, Yarzebski J, Gore JM, Lessard D, Goldberg RG. Population-based outcomes for the invasive management strategy for non-Q wave myocardial infarction. Am Heart Journal 2002; 143:6: 1033-1039.
Dauerman HL, Goldberg RJ, White K, Gurfinkel E, Lopes de Sa E, Gore JM. Stents, revascularization and outcomes for patients in cardiogenic shock: Findings from the Global Registry of Acute Coronary Events Am J Cardiol 2002;90:838-842.
